CH628628A5 - Process for the preparation of cyclic compounds - Google Patents
Process for the preparation of cyclic compounds Download PDFInfo
- Publication number
- CH628628A5 CH628628A5 CH954377A CH954377A CH628628A5 CH 628628 A5 CH628628 A5 CH 628628A5 CH 954377 A CH954377 A CH 954377A CH 954377 A CH954377 A CH 954377A CH 628628 A5 CH628628 A5 CH 628628A5
- Authority
- CH
- Switzerland
- Prior art keywords
- solution
- carbomethoxy
- formula
- amino
- hydrochloride
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 10
- 238000002360 preparation method Methods 0.000 title claims description 6
- 150000001923 cyclic compounds Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 15
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 5
- -1 ester hydrochloride Chemical class 0.000 claims description 5
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 239000012435 aralkylating agent Substances 0.000 claims description 2
- BPGYXWDXHQSGHM-UHFFFAOYSA-N methyl 4-amino-5-propylthiophene-3-carboxylate;hydrochloride Chemical compound Cl.CCCC=1SC=C(C(=O)OC)C=1N BPGYXWDXHQSGHM-UHFFFAOYSA-N 0.000 claims description 2
- 150000003141 primary amines Chemical class 0.000 claims description 2
- 230000002152 alkylating effect Effects 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 63
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 45
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 36
- 239000000243 solution Substances 0.000 description 31
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 21
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 20
- 229910001868 water Inorganic materials 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 14
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 14
- 229960003767 alanine Drugs 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 235000004279 alanine Nutrition 0.000 description 11
- 239000008346 aqueous phase Substances 0.000 description 10
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 10
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 10
- 238000002844 melting Methods 0.000 description 10
- 230000008018 melting Effects 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 235000012000 cholesterol Nutrition 0.000 description 9
- 239000012230 colorless oil Substances 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 9
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- 229930195729 fatty acid Natural products 0.000 description 8
- 150000004665 fatty acids Chemical class 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000000284 extract Substances 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 210000003494 hepatocyte Anatomy 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000004132 lipogenesis Effects 0.000 description 5
- LDTLDBDUBGAEDT-UHFFFAOYSA-N methyl 3-sulfanylpropanoate Chemical compound COC(=O)CCS LDTLDBDUBGAEDT-UHFFFAOYSA-N 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 230000004136 fatty acid synthesis Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 150000002923 oximes Chemical class 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- SIHCENGFXNSHNG-UHFFFAOYSA-N 2-(2-carboxyethylsulfanyl)propanoic acid Chemical compound OC(=O)C(C)SCCC(O)=O SIHCENGFXNSHNG-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N anhydrous n-heptane Natural products CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 150000004292 cyclic ethers Chemical class 0.000 description 2
- 150000005690 diesters Chemical class 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 2
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- ORSIRXYHFPHWTN-UHFFFAOYSA-N ethyl 2-bromopentanoate Chemical compound CCCC(Br)C(=O)OCC ORSIRXYHFPHWTN-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- WZLILWQALWZCCL-UHFFFAOYSA-N methyl 2-(3-methoxy-3-oxopropyl)sulfanylpentanoate Chemical compound CCCC(C(=O)OC)SCCC(=O)OC WZLILWQALWZCCL-UHFFFAOYSA-N 0.000 description 2
- QDKGGYGIXLSTDT-UHFFFAOYSA-N methyl 3-(2-methoxy-2-oxo-1-phenylethyl)sulfanylpropanoate Chemical compound COC(=O)CCSC(C(=O)OC)C1=CC=CC=C1 QDKGGYGIXLSTDT-UHFFFAOYSA-N 0.000 description 2
- JBGSZTPWSVLJJW-UHFFFAOYSA-N methyl 4-amino-5-phenylthiophene-3-carboxylate;hydrochloride Chemical compound Cl.COC(=O)C1=CSC(C=2C=CC=CC=2)=C1N JBGSZTPWSVLJJW-UHFFFAOYSA-N 0.000 description 2
- VGVKSIJTGAHDQX-UHFFFAOYSA-N methyl 4-amino-5-propan-2-ylthiophene-3-carboxylate;hydrochloride Chemical compound Cl.COC(=O)C1=CSC(C(C)C)=C1N VGVKSIJTGAHDQX-UHFFFAOYSA-N 0.000 description 2
- AAMVDSWOJNQRRJ-UHFFFAOYSA-N methyl 4-hydroxyimino-5-methylthiolane-3-carboxylate Chemical compound COC(=O)C1CSC(C)C1=NO AAMVDSWOJNQRRJ-UHFFFAOYSA-N 0.000 description 2
- ISZVLVQGQLASQS-UHFFFAOYSA-N methyl 4-hydroxyimino-5-propan-2-ylthiolane-3-carboxylate Chemical compound COC(=O)C1CSC(C(C)C)C1=NO ISZVLVQGQLASQS-UHFFFAOYSA-N 0.000 description 2
- LISZJZABYLSBPM-UHFFFAOYSA-N methyl 4-hydroxyimino-5-propylthiolane-3-carboxylate Chemical compound CCCC1SCC(C(=O)OC)C1=NO LISZJZABYLSBPM-UHFFFAOYSA-N 0.000 description 2
- KCSVQSYESUPMQQ-UHFFFAOYSA-N methyl 4-oxo-5-phenylthiolane-3-carboxylate Chemical compound O=C1C(C(=O)OC)CSC1C1=CC=CC=C1 KCSVQSYESUPMQQ-UHFFFAOYSA-N 0.000 description 2
- OFBRZVXWOABKSL-UHFFFAOYSA-N methyl 4-oxo-5-propan-2-ylthiolane-3-carboxylate Chemical compound COC(=O)C1CSC(C(C)C)C1=O OFBRZVXWOABKSL-UHFFFAOYSA-N 0.000 description 2
- XAKJQFQGSGODID-UHFFFAOYSA-N methyl 4-oxo-5-propylthiolane-3-carboxylate Chemical compound CCCC1SCC(C(=O)OC)C1=O XAKJQFQGSGODID-UHFFFAOYSA-N 0.000 description 2
- HLNPATHSTGXZRT-UHFFFAOYSA-N methyl 5-methyl-4-oxothiolane-3-carboxylate Chemical compound COC(=O)C1CSC(C)C1=O HLNPATHSTGXZRT-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- JAQKNILFSHWHDS-UHFFFAOYSA-N 3-amino-2-methyl-2H-thiophene-3-carboxylic acid Chemical compound NC1(C(SC=C1)C)C(=O)O JAQKNILFSHWHDS-UHFFFAOYSA-N 0.000 description 1
- ZXGGUYQIMVTIEC-UHFFFAOYSA-N 4-amino-5-phenylthiophene-3-carboxylic acid Chemical compound OC(=O)C1=CSC(C=2C=CC=CC=2)=C1N ZXGGUYQIMVTIEC-UHFFFAOYSA-N 0.000 description 1
- NWERDHCQVWJODH-UHFFFAOYSA-N 4-amino-5-propylthiophene-3-carboxylic acid Chemical compound CCCC=1SC=C(C(O)=O)C=1N NWERDHCQVWJODH-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- DEFJQIDDEAULHB-UHFFFAOYSA-N Alanyl-alanine Chemical compound CC(N)C(=O)NC(C)C(O)=O DEFJQIDDEAULHB-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000008002 Krebs-Henseleit bicarbonate buffer Substances 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 1
- XIMFCGSNSKXPBO-UHFFFAOYSA-N ethyl 2-bromobutanoate Chemical compound CCOC(=O)C(Br)CC XIMFCGSNSKXPBO-UHFFFAOYSA-N 0.000 description 1
- ARFLASKVLJTEJD-UHFFFAOYSA-N ethyl 2-bromopropanoate Chemical compound CCOC(=O)C(C)Br ARFLASKVLJTEJD-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 229910000039 hydrogen halide Inorganic materials 0.000 description 1
- 239000012433 hydrogen halide Substances 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- IFDLYTVTWMMYFZ-UHFFFAOYSA-N methyl 4-amino-5-ethylthiophene-3-carboxylate;hydrochloride Chemical compound Cl.CCC=1SC=C(C(=O)OC)C=1N IFDLYTVTWMMYFZ-UHFFFAOYSA-N 0.000 description 1
- QJXLLLDJKRNMEL-UHFFFAOYSA-N methyl 4-amino-5-methylthiophene-3-carboxylate;hydrochloride Chemical compound Cl.COC(=O)C1=CSC(C)=C1N QJXLLLDJKRNMEL-UHFFFAOYSA-N 0.000 description 1
- RAWYOFQTXRJKNS-UHFFFAOYSA-N methyl 4-hydroxyimino-5-phenylthiolane-3-carboxylate Chemical compound ON=C1C(C(=O)OC)CSC1C1=CC=CC=C1 RAWYOFQTXRJKNS-UHFFFAOYSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- IRGDRSIZYKSOPT-UHFFFAOYSA-N thiophen-2-ylazanium;chloride Chemical compound Cl.NC1=CC=CS1 IRGDRSIZYKSOPT-UHFFFAOYSA-N 0.000 description 1
- 150000003577 thiophenes Chemical class 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71685376A | 1976-08-23 | 1976-08-23 | |
| US71685476A | 1976-08-23 | 1976-08-23 | |
| US82052177A | 1977-08-01 | 1977-08-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH628628A5 true CH628628A5 (en) | 1982-03-15 |
Family
ID=27418961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH954377A CH628628A5 (en) | 1976-08-23 | 1977-08-03 | Process for the preparation of cyclic compounds |
Country Status (21)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6232765Y2 (enrdf_load_stackoverflow) * | 1981-02-28 | 1987-08-21 | ||
| US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US6251920B1 (en) | 1993-05-13 | 2001-06-26 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
| US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| DE69435137D1 (de) | 1993-05-13 | 2008-10-16 | Poniard Pharmaceuticals Inc | Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind |
| AU6959898A (en) * | 1997-04-11 | 1998-11-11 | David J. Grainger | Compounds and therapies for the prevention of vascular and non-vascular pathol ogies |
| US6613083B2 (en) | 2001-05-02 | 2003-09-02 | Eckhard Alt | Stent device and method |
| DE102004063191A1 (de) | 2004-12-29 | 2006-07-13 | Bayer Cropscience Ag | Verfahren zur Herstellung von substituierten 2-Alkoxycarbonyl-3-aminothiophenen |
| NZ587261A (en) * | 2008-02-29 | 2012-05-25 | Nissan Chemical Ind Ltd | Process for producing thiophene compound and intermediate thereof |
| AR130733A1 (es) | 2022-10-14 | 2025-01-15 | Adama Agan Ltd | Proceso para la preparación de aminotiofeno sustituido |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2502421A (en) * | 1944-08-28 | 1950-04-04 | Parke Davis & Co | Tetrahydrothiophenes |
| US2502423A (en) * | 1944-12-23 | 1950-04-04 | Parke Davis & Co | 4-carbalkoxy-3-keto-2-substituted tetrahydrothiophene oximes |
| US2502424A (en) * | 1944-12-23 | 1950-04-04 | Parke Davis & Co | 3-acylamino-4-carboalkoxy-2-omega-ralkylthiophenes |
| US2443598A (en) * | 1944-12-23 | 1948-06-22 | Parke Davis & Co | 3-amino-4-carbethoxy-2-alkyl derivatives of thiophene |
-
1977
- 1977-08-03 CH CH954377A patent/CH628628A5/de not_active IP Right Cessation
- 1977-08-19 FR FR7725379A patent/FR2365566A1/fr active Granted
- 1977-08-22 LU LU78003A patent/LU78003A1/xx unknown
- 1977-08-22 AT AT607477A patent/AT359486B/de not_active IP Right Cessation
- 1977-08-22 FI FI772494A patent/FI66859C/fi not_active IP Right Cessation
- 1977-08-22 HU HU77HO2009A patent/HU179484B/hu not_active IP Right Cessation
- 1977-08-22 DK DK372177A patent/DK150484C/da active
- 1977-08-22 NZ NZ184981A patent/NZ184981A/xx unknown
- 1977-08-22 NL NL7709246A patent/NL7709246A/xx not_active Application Discontinuation
- 1977-08-22 JP JP9963877A patent/JPS5340755A/ja active Granted
- 1977-08-22 DE DE2737738A patent/DE2737738C2/de not_active Expired
- 1977-08-22 AR AR268888A patent/AR222453A1/es active
- 1977-08-22 MC MC771256A patent/MC1156A1/xx unknown
- 1977-08-22 IL IL52792A patent/IL52792A/xx unknown
- 1977-08-22 IT IT26845/77A patent/IT1143757B/it active
- 1977-08-22 BE BE180354A patent/BE858012A/xx not_active IP Right Cessation
- 1977-08-22 GB GB35098/77A patent/GB1587084A/en not_active Expired
- 1977-08-22 NO NO772917A patent/NO148673C/no unknown
- 1977-08-22 AU AU28092/77A patent/AU509956B2/en not_active Expired
- 1977-08-22 IE IE1751/77A patent/IE45470B1/en unknown
- 1977-08-22 ES ES461796A patent/ES461796A1/es not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| NL7709246A (nl) | 1978-02-27 |
| NO772917L (no) | 1978-02-24 |
| MC1156A1 (fr) | 1978-04-17 |
| ATA607477A (de) | 1980-04-15 |
| IL52792A0 (en) | 1977-10-31 |
| DK150484B (da) | 1987-03-09 |
| JPS6121235B2 (enrdf_load_stackoverflow) | 1986-05-26 |
| LU78003A1 (enrdf_load_stackoverflow) | 1978-09-14 |
| NO148673C (no) | 1983-11-23 |
| IL52792A (en) | 1981-06-29 |
| AT359486B (de) | 1980-11-10 |
| JPS5340755A (en) | 1978-04-13 |
| ES461796A1 (es) | 1978-12-16 |
| NO148673B (no) | 1983-08-15 |
| IT1143757B (it) | 1986-10-22 |
| DE2737738A1 (de) | 1978-03-09 |
| FI772494A7 (fi) | 1978-02-24 |
| FI66859B (fi) | 1984-08-31 |
| FR2365566B1 (enrdf_load_stackoverflow) | 1980-12-26 |
| GB1587084A (en) | 1981-03-25 |
| DK372177A (da) | 1978-02-24 |
| FI66859C (fi) | 1984-12-10 |
| DK150484C (da) | 1987-10-05 |
| IE45470B1 (en) | 1982-09-08 |
| NZ184981A (en) | 1980-08-26 |
| AU2809277A (en) | 1979-03-01 |
| BE858012A (fr) | 1978-02-22 |
| IE45470L (en) | 1978-02-23 |
| FR2365566A1 (fr) | 1978-04-21 |
| AU509956B2 (en) | 1980-06-05 |
| DE2737738C2 (de) | 1987-01-29 |
| HU179484B (en) | 1982-10-28 |
| AR222453A1 (es) | 1981-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE1645971C3 (de) | (lndazol-3-yl)-oxyessigsäurederivate, Verfahren zu ihrer Herstellung und Mittel mit entzündungshemmender Wirkung | |
| CH615920A5 (enrdf_load_stackoverflow) | ||
| CH628628A5 (en) | Process for the preparation of cyclic compounds | |
| DE1948144A1 (de) | 3,4-Dihydronaphthalinonoxy-2-hydroxypropylderivate und Verfahren zu ihrer Herstellung | |
| DE2537070C2 (enrdf_load_stackoverflow) | ||
| CH637403A5 (de) | Verfahren zur herstellung von diuretisch wirksamen 17-alpha-pregnanderivaten. | |
| DE2535147A1 (de) | 2-thiol-4,5-diphenyloxazol-s-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel | |
| EP0177907B1 (de) | Neue 2-Pyridin-thiol-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate | |
| DE2431561A1 (de) | Cycloalkylphenoxycarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel | |
| DE2509168A1 (de) | Neue nitroimidazole | |
| DD150060A5 (de) | Verfahren zur herstellung von neuen phenthiazin-derivaten | |
| AT349481B (de) | Verfahren zur herstellung von neuen morpholinderivaten, ihren n-oxiden und salzen | |
| DE1493513C3 (de) | Sulfamylanthranilsäuren, deren therapeutisch verwendbare Salze, Verfahren zu ihrer Herstellung und diese enthaltenden pharmazeutischen Präparate | |
| DE1287582B (de) | Verfahren zur Herstellung von disubstituierten Isoxazol-Verbindungen und ihrer nicht toxischen Salze | |
| DE3641907A1 (de) | 4h-benzo(4,5)cyclohepta(1,2-b)thiophen derivate | |
| DE2336107A1 (de) | Phenoxycarbonsaeurederivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneipraeparate | |
| DE2013023A1 (de) | 2,3,4,4a-Tetrahydro-10 H-I,2-oxazino (3,2-b)(1,3)benzoxazin-10-one | |
| EP0034746B1 (de) | 5-Sulfamoyl-orthanilsäuren, Verfahren zu ihrer Herstellung, diese enthaltende Heilmittel und die Verbindungen zur Verwendung als Heilmittel | |
| DE1545764C (de) | p Chlorphenvhsopropylcarbinol nico tinsaureester | |
| AT337709B (de) | Verfahren zur herstellung von neuen 1-phthalazonderivaten | |
| AT288398B (de) | Verfahren zur Herstellung von neuen Zimtsäureamiden | |
| AT288399B (de) | Verfahren zur Herstellung von neuen Zimtsäureamiden | |
| AT295516B (de) | Verfahren zur Herstellung neuer cyclischer Amidine und ihrer Salze | |
| AT387018B (de) | Verfahren zur herstellung von neuen kondensierten as-triazin-derivaten | |
| DE2615161A1 (de) | Omega-aminoalkoxy-alkane, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUE | Assignment |
Owner name: F. HOFFMANN-LA ROCHE AG |
|
| PL | Patent ceased | ||
| PL | Patent ceased |